Compare Charles River Laboratories Intl. Inc (CRL) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Cintas Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Cintas Corporation trades at $202.61 (market cap $79.86B). The key difference: Cintas Corporation is far larger — about 5.6× Charles River Laboratories Intl. Inc's market cap, and Cintas Corporation pays a 1.03% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Cintas Corporation for 125 Days on average.
| CRL | CTAS | |
|---|---|---|
Market Cap | $14.23B | $79.86B |
Volume | 1,176,885 | 1,323,583 |
Sector | Health | Industrials |
52-Week High | $310.77 | $216.53 |
52-Week Low | $149.93 | $163.55 |
Typical Hold Time | 33 Days | 125 Days |
Enterprise Value | $17.06B | $82.33B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Cintas (CTAS) trades at $202.41, up 2.65% on the day, reflecting strong momentum after recent earnings beat. The stock exhibits a bullish technical setup with price above key moving averages. Fundamentally, the company reported Q1 2027 revenue of $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 surpassing estimates. Robust profitability is evident with a net income margin of 17.82% and ROE of 41.25%. Recent news highlights raised fiscal 2027 guidance, signaling management confidence in continued growth driven by organic expansion and margin gains.
The outlook for CTAS remains positive, supported by consistent revenue growth, high profitability, and bullish analyst sentiment with a consensus price target of $234.60. Key opportunities include sustained demand for uniform rental and workplace services, while risks involve elevated valuation multiples and potential economic sensitivity. The stock's current trajectory suggests further upside if execution remains strong, though investors should monitor margin sustainability and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
